|
1
|
Hu Y and Li S: Survival regulation of
leukemia stem cells. Cell Mol Life Sci. 73:1039–1050. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Passegué E and Weisman IL: Leukemic stem
cells: Where do they come from? Stem Cell Rev. 1:181–188. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Styczynski J and Drewa T: Leukemic stem
cells: From metabolic pathways and signaling to a new concept of
drug resistance targeting. Acta Biochim Pol. 54:717–726.
2007.PubMed/NCBI
|
|
4
|
Guzman ML, Neering SJ, Upchurch D, Grimes
B, Howard DS, Rizzieri DA, Luger SM and Jordan CT: Nuclear
factor-kappaB is constitutively activated in primitive human acute
myelogenous leukemia cells. Blood. 98:2301–2307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Won EJ, Kim HR, Park RY, Choi SY, Shin JH,
Suh SP, Ryang DW, Szardenings M and Shin MG: Direct confirmation of
quiescence of CD34+CD38-leukemia stem cell populations using single
cell culture, their molecular signature and clinicopathological
implications. BMC Cancer. 15:2172015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Irons RD and Stillman WS: Cell
proliferation and differentiation in chemical leukemogenesis. Stem
Cells. 11:235–242. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peng C, Chen Y, Li D and Li S: Role of
Pten in leukemia stem cells. Oncotarget. 1:156–160. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
MacDonald TL, Labroli MA and Tepe JJ: 7.16
- DNA Topoisomerase InhibitorsComprehensive Natural Products
Chemistry. 7. Elsevier Ltd.; Philadelphia, PA: pp. 593–614. 1999,
View Article : Google Scholar
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He K, Yu P, Xing HY, Li Y, Tian Z, Wang M,
Tang KJ and Rao Q: Resistance of leukemia KG1a cells with positive
N-cadherin in phase G(0) against killing activity of VP16. Zhongguo
Shi Yan Xue Ye Xue Za Zhi. 19:1102–1106. 2011.(In Chinese).
PubMed/NCBI
|
|
11
|
Colado E, Paino T, Maiso P, Ocio EM, Chen
X, Alvarez-Fernández S, Gutiérrez NC, Martín-Sánchez J,
Flores-Montero J, San Segundo L, et al: Zalypsis has in vitro
activity in acute myeloid blasts and leukemic progenitor cells
through the induction of a DNA damage response. Haematologica.
96:687–695. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Döhner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA,
et al: Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood.
129:424–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vergez F, Green AS, Tamburini J, Sarry JE,
Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N,
Ifrah N, et al: High levels of CD34+CD38low/−CD123+ blasts are
predictive of an adverse outcome in acute myeloid leukemia: A
Groupe Ouest-Est Des Leucemies Aigues et maladies du sang (GOELAMS)
study. Haematologica. 96:1792–1798. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
She M, Niu X, Chen X, Li J, Zhou M, He Y,
Le Y and Guo K: Resistance of leukemic stem-like cells in AML cell
line KG1a to natural killer cell-mediated cytotoxicity. Cancer
Lett. 318:173–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Long J, Liu S, Li K, Zhou X, Zhang P and
Zou L: High proportion of CD34+/CD38-cells is positively correlated
with poor prognosis in newly diagnosed childhood acute
lymphoblastic leukemia. Leuk Lymphoma. 55:611–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sohl SJ, Schnur JB and Montgomery GH: A
meta-analysis of the relationship between response expectancies and
cancer treatment-related side effects. J Pain Symptom Manage.
38:775–784. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Horton SJ and Huntly BJ: Recent advances
in acute myeloid leukemia stem cell biology. Haematologica.
97:966–974. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chávez-González A, Dorantes-Acosta E,
Moreno-Lorenzana D, Alvarado-Moreno A, Arriaga-Pizano L and Mayani
H: Expression of CD90, CD96, CD117, and CD123 on different
hematopoietic cell populations from pediatric patients with acute
myeloid leukemia. Arch Med Res. 45:343–350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tettamanti S, Biondi A, Biagi E and Bonnet
D: CD123 AML targeting by chimeric antigen receptors: A novel magic
bullet for AML therapeutics? Oncoimmunology. 3:e288352014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu L, Reader JC, Chen C, Zhao XF, Ha JS,
Lee C, York T, Gojo I, Baer MR and Ning Y: Activation of a novel
palmitoyltransferase ZDHHC14 in acute biphenotypic leukemia and
subsets of acute myeloid leukemia. Leukemia. 25:367–371. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zulfikar O, Koc B and Kebudi R: The oue
center experience. J Clin Oncol. 31:136–139. 2013.
|
|
22
|
Majeti R: Monoclonal antibody therapy
directed against human acute myeloid leukemia stem cells. Oncogene.
30:1009–1019. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song QX, Wu Y and Chen YZ: The effect of
CD44 antibody-HI44a on proliferation and differentiation of HL-60
cells. Chine Pharmacol Bulletin. 3:222011.
|
|
24
|
Misaghian N, Ligresti G, Steelman LS,
Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M,
Tafuri A, et al: Targeting the leukemic stem cell: The holy grail
of leukemia therapy. Leukemia. 23:25–42. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hope KJ, Jin L and Dick JE: Human acute
myeloid leukemia stem cells. Arch Med Res. 34:507–514. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pollyea DA, Gutman JA, Gore L, Smith CA
and Jordan CT: Targeting acute myeloid leukemia stem cells: A
review and principles for the development of clinical trials.
Haematologica. 99:1277–1284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang C and Chen Y: The study of molecular
mechanism of leukemia stem cell resistance. J Mol Diagno Ther.
3:203–206. 2009.
|
|
28
|
Saito Y, Uchida N, Tanaka S, Suzuki N,
Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, et
al: Induction of cell cycle entry eliminates human leukemia stem
cells in a mouse model of AML. Nat Biotechnol. 28:275–280.
2010.PubMed/NCBI
|
|
29
|
Song N, He WZ, Wang ZM and Ren YL: Effects
of serum containing Zuigui pill, Yougui pill and their disassembled
prescriptions on the cell cycle and cell apoptosis of bone marrow
mesenchymal stem cells in osteogenic differentiation. Chin J Trad
Chin Med Pharm. 5:772013.
|
|
30
|
Wu H, Goel V and Haluska FG: PTEN
signaling pathways in melanoma. Oncogene. 22:3113–3122. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morotti A, Panuzzo C, Crivellaro S, Carrà
G, Torti D, Guerrasio A and Saglio G: The Role of PTEN in myeloid
malignancies. Hematol Rep. 7:58442015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheung AM and Mak TW: PTEN in the
haematopoietic system and its therapeutic indications. Trends Mol
Med. 12:503–505. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peng C, Chen Y, Yang Z, Zhang H, Osterby
L, Rosmarin AG and Li S: PTEN is a tumor suppressor in CML stem
cells and BCR-ABL-induced leukemias in mice. Blood. 115:626–635.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu R, Wang X and Wang J: Study on the
expression of Flt3 and N-ras genes human leukemia stem cells using
RT-PCT. Zhe Int Trad Chin West Med. 5:278–280. 2009.
|
|
35
|
Cowell IG and Austin CA: Mechanism of
generation of therapy related leukemia in response to
anti-topoisomerase II agents. Int J Environ Res Public Health.
9:2075–2091. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang JC and Kirkegaard K: DNA
topoisomerases. Gene Amplif Anal. 2:455–473. 1981.PubMed/NCBI
|
|
37
|
Liu MY, Wang WZ, Liao FF, Wu QQ, Lin XH,
Chen YH, Cheng L, Jin XB and Zhu JY: Selective and effective
targeting of chronic myeloid leukemia stem cells by topoisomerase
II inhibitor etoposide in combination with imatinib mesylate in
vitro. Cell Biol Int. 41:16–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi Z and Yang W: The effect and
underlying mechanism of liushenpill in reversing multidrug
resistance in leukemia cells. J Tian Uni Trad Chin Med. 1:11–13.
2007.
|
|
39
|
Kim SS, Seong S and Kim SY: Synergistic
effect of ginsenoside Rg3 with verapamil on the modulation of
multidrug resistance in human acute myeloid leukemia cells. Oncol
Lett. 7:1265–1269. 2014.PubMed/NCBI
|
|
40
|
Li J and Liu XB: Advances in medicine of
toxicity and synergistic effects in cancer treatment. J Pharmaceut
Res. 4:229–231. 2015.
|
|
41
|
Long X, Geng Y and Guo Q: Recent progress
in anti-tumor medicine and the role of the active ingredients in
recent years. Chin Arch Tradl Chin Med. 4:862–864. 2015.
|
|
42
|
Yan L and Shi Z: Clinical study on
reversal of multidrug resistance in refractory acute leukemia by
Supplementing qi and nourishing yin. J Beij Uni Trad Chin Med.
1:68–72. 2015.
|
